These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

81 related articles for article (PubMed ID: 538683)

  • 21. Cyfra 21-1: a serological help for detection of distant metastases in head and neck cancer.
    Maass JD; Hoffmann-Fazel A; Goeroegh T; Hoffmann M; Meyer JE; Gottschlich S; Rudert H; Maune S
    Anticancer Res; 2000; 20(3B):2241-3. PubMed ID: 10928185
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Analytical and clinical evaluation of CYFRA 21-1 by electrochemiluminescent immunoassay in head and neck squamous cell carcinoma.
    Kuropkat C; Werner JA
    J Laryngol Otol; 2003 Dec; 117(12):1007-8; author reply 1008-9. PubMed ID: 14738621
    [No Abstract]   [Full Text] [Related]  

  • 23. Serum magnesium levels in patients with head and neck cancer.
    Kohli GS; Bhargava A; Goel H; Yadav SP; Saini AS; Singh GP; Lal H
    Magnesium; 1989; 8(2):77-86. PubMed ID: 2755215
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Immunology of head and neck cancers.
    Newbill ET; Johns ME
    Crit Rev Clin Lab Sci; 1983; 19(1):1-25. PubMed ID: 6201320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Total lymphocyte and T lymphocyte subpopulation levels in head and neck squamous cell carcinomas.
    Soysal V; Yigitbasi OG; Alper M; Patiroglu T; Güney E
    J Exp Clin Cancer Res; 1998 Jun; 17(2):207-12. PubMed ID: 9700582
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Head and neck squamous cell carcinoma: measurement of plasma parathyroid hormone-related protein and serum and urine calcium concentrations.
    Sellers RS; Schuller DE; Sharma PK; Tannehill-Gregg SH; Capen CC; Rosol TJ
    Otolaryngol Head Neck Surg; 2000 Nov; 123(5):558-62. PubMed ID: 11077340
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Serum concentrations of laminin gamma2 fragments in patients with head and neck squamous cell carcinoma.
    Kuratomi Y; Sato S; Monji M; Shimazu R; Tanaka G; Yokogawa K; Inoue A; Inokuchi A; Katayama M
    Head Neck; 2008 Aug; 30(8):1058-63. PubMed ID: 18446818
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Serum levels of matrix metalloproteinase-2 and -9 in patients with head and neck squamous cell carcinoma.
    Riedel F; Götte K; Schwalb J; Hörmann K
    Anticancer Res; 2000; 20(5A):3045-9. PubMed ID: 11062721
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Evaluation of glycoproteins as prognosticators in head and neck malignancy.
    Bathi RJ; Nandimath K; Kannan N; Shetty P
    Indian J Dent Res; 2001; 12(2):93-9. PubMed ID: 11665403
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The prognostic value of mononucleated cell levels in cancer patients.
    Elias EG
    Md Med J; 1991 Apr; 40(4):267-8. PubMed ID: 2034062
    [No Abstract]   [Full Text] [Related]  

  • 31. [Immunity indices of patients with locally disseminated malignant neoplasms of the head and neck].
    Bulbuk GA
    Vopr Onkol; 1982; 28(4):57-9. PubMed ID: 7090271
    [TBL] [Abstract][Full Text] [Related]  

  • 32. p53 autoantibodies as tumor marker in head and neck squamous cell cancer.
    Gottschlich S; Hoffmann M; Maass JD; Görörgh T; Buhmann V; Hoffmann-Fazel A; Rudert H; Maune S
    Anticancer Res; 2003; 23(2A):913-5. PubMed ID: 12820322
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Serum acute phase proteins in nasopharyngeal carcinoma and laryngeal cancers].
    Chen P
    Zhonghua Er Bi Yan Hou Ke Za Zhi; 1989; 24(3):174-6, 190. PubMed ID: 2484505
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Serum protein profile analysis following definitive treatment in patients with head and neck squamous cell carcinoma.
    Gourin CG; Moretz WH; Weinberger PM; Xia ZS; Liu Z; Terris DJ; Adam BL
    Arch Otolaryngol Head Neck Surg; 2007 Nov; 133(11):1125-30. PubMed ID: 18025317
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The need for a better prognostic staging system in patients with metastatic cutaneous squamous cell carcinoma of the head and neck.
    Palme CE; MacKay SG; Kalnins I; Morgan GJ; Veness MJ
    Curr Opin Otolaryngol Head Neck Surg; 2007 Apr; 15(2):103-6. PubMed ID: 17413411
    [TBL] [Abstract][Full Text] [Related]  

  • 36. CYFRA 8/18 in head and neck cancer.
    Maass JD; Niemann AM; Lippert BM; Gottschlich S; Folz BJ; Werner JA
    Anticancer Res; 1999; 19(4A):2699-701. PubMed ID: 10470223
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CYFRA 21-1 is not superior to SCC antigen and CEA in head and neck squamous cell cancer.
    Wollenberg B; Jan V; Schmit UM; Hofmann K; Stieber P; Fateh-Moghadam A
    Anticancer Res; 1996; 16(5B):3117-24. PubMed ID: 8920778
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The significance of ferritin, lipid-associated sialic acid, CEA, squamous cell carcinoma (SCC) antigen, and CYFRA 21-1 levels in SCC of the head and neck.
    Inal E; Laçin M; Asal K; Ceylan A; Köybaşioğlu A; Ileri F; Uslu SS
    Kulak Burun Bogaz Ihtis Derg; 2004; 12(1-2):23-30. PubMed ID: 16010093
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Tumor antigen phenotype, biologic staging, and prognosis in head and neck squamous carcinoma.
    Wolf GT; Carey TE
    J Natl Cancer Inst Monogr; 1992; (13):67-74. PubMed ID: 1389697
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Soluble interleukin-2 receptor and metalloproteinase-9 expression in head and neck cancer: prognostic value and analysis of their relationships.
    El Houda Agueznay N; Badoual C; Hans S; Gey A; Vingert B; Peyrard S; Quintin-Colonna F; Ravel P; Bruneval P; Roncelin S; Lelongt B; Bertoglio J; Fridman WH; Brasnu D; Tartour E
    Clin Exp Immunol; 2007 Oct; 150(1):114-23. PubMed ID: 17680822
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.